July 8 (Reuters) - Telix Pharmaceuticals Ltd TLX.AX :
* RECEIVES US FDA FEEDBACK ON PHASE 3 TRIAL DESIGN FOR PROSTATE CANCER THERAPY PRODUCT
* INTENDS TO FILE A PHASE 3 IND FOR TLX591 PRIOR TO END OF 2020
July 8 (Reuters) - Telix Pharmaceuticals Ltd TLX.AX :
* RECEIVES US FDA FEEDBACK ON PHASE 3 TRIAL DESIGN FOR PROSTATE CANCER THERAPY PRODUCT
* INTENDS TO FILE A PHASE 3 IND FOR TLX591 PRIOR TO END OF 2020